I'm liking this from the 12/26/2019 PR. “The st
Post# of 72445
(Total Views: 430)
Posted On: 02/16/2020 11:05:49 AM
I'm liking this from the 12/26/2019 PR.
“The study is expected to be a quick one, with dosing completed within several weeks of commencement, and, if successful, would translate into numerous potential positive outcomes for the company,” noted Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are optimistic about the safety and efficacy profile of Brilacidin in IBD based on our prior clinical trial in Ulcerative Proctitis/Ulcerative Proctosigmoiditis, and are further encouraged that our out-licensing partner in this indication is planning to start trials mid year-2020. Now the key to differentiation and really catching the attention of big pharma for the opportunity is efficient delivery of the drug directly into the colon.”
“The study is expected to be a quick one, with dosing completed within several weeks of commencement, and, if successful, would translate into numerous potential positive outcomes for the company,” noted Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We are optimistic about the safety and efficacy profile of Brilacidin in IBD based on our prior clinical trial in Ulcerative Proctitis/Ulcerative Proctosigmoiditis, and are further encouraged that our out-licensing partner in this indication is planning to start trials mid year-2020. Now the key to differentiation and really catching the attention of big pharma for the opportunity is efficient delivery of the drug directly into the colon.”
(10)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Leo Took The Money and Ran